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LI-CORThe ubiquitin–proteasome system is an essential cellular process that plays a fundamental role in the
regulation of protein stability. This pathway is tightly controlled by a sequential cascade of enzymatic
steps that culminates in the formation of a poly-ubiquitin chain onto the substrate protein targeted for
26S proteasome degradation. Through a process of co-evolution viruses have evolved mechanisms to uti-
lize or suppress this pathway in order to enhance their replication and spread. One of the ﬁrst proteins to
be expressed during herpes simplex virus 1 (HSV-1) infection is ICP0, a viral RING-ﬁnger E3 ubiquitin
ligase that targets a variety of cellular proteins for ubiquitination and proteasome-dependent degrada-
tion. This activity is required in order for ICP0 to efﬁciently stimulate the onset of HSV-1 lytic infection
and viral reactivation from latency. While it is clear that the RING-ﬁnger domain of ICP0 plays an impor-
tant role in the biology of HSV-1, methods for accurately quantifying its biochemical activity are currently
lacking. Here we describe a protocol that enables the quantitative measurement of the ubiquitin ligase
activity of ICP0 using near-infrared (IR) western blot imaging. The use of such imaging technology pro-
vides an accurate means to examine the biochemical and kinetic parameters of RING-ﬁnger ubiquitin
ligases in solution, and may provide signiﬁcant application for inhibitor studies.
Crown Copyright  2015 Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The ubiquitin pathway is an essential cellular process in all
eukaryotes. The post-translational modiﬁcation (PTM) of proteins
through the covalent attachment of ubiquitin, itself a small 76
amino acid protein, is known to play a fundamental role in the reg-
ulation of many aspects of cell biology. The process of ubiquitin
modiﬁcation (ubiquitination) requires an ATP-dependent cascade
of enzymatic steps; including ubiquitin activation, conjugation,
and ligation by E1, E2, and E3 pathway component enzymes,
respectively (schematically summarized in Fig. 1). E3 ubiquitin
ligases not only provide substrate-speciﬁcity, but also assist in the
enzymatic transfer of ubiquitin from charged E2 ubiquitin
conjugating enzymes onto substrate proteins undergoingmodiﬁca-
tion [1]. The attachment of ubiquitin typically occurs through the
formation of an isopeptide bond between the C-terminal glycine
residue of ubiquitin and the amino side chain of a solvent exposed
lysine residue within the substrate protein. This initial mono-
ubiquitination event can be subsequently extended through the
sequential addition of ubiquitin molecules onto lysine residueswithin the attached ubiquitin molecule itself, leading to the forma-
tion of an anchored poly-ubiquitin chain (Fig. 1; reviewed in [2]). As
ubiquitin contains seven lysine residues, each of which can serve as
an acceptor site for ubiquitin attachment, a structurally diverse
range of ubiquitin chain types can be formed that inﬂuence various
aspects of protein biochemistry and cell biology; including the cell
cycle (Lysine-11 linked chains), proteasome-mediated degradation
(Lysine-48 linked chains), as well as DNA repair and host immune
signaling pathways (Lysine-63 linked chains; reviewed in [3]).
Due to the importance of the ubiquitin–proteasome system,
viruses have evolved mechanisms to manipulate this pathway to
their advantage in order to enhance their replication and spread
(reviewed in [4,5]). One of the ﬁrst proteins to be expressed during
herpes simplex virus 1 (HSV-1) infection is ICP0 (infected cell pro-
tein 0), a C3HC4 RING-ﬁnger E3 ubiquitin ligase [6]. Genetic stud-
ies have shown that ICP0 is required to efﬁciently stimulate the
onset of HSV-1 lytic infection and productive reactivation of viral
genomes from latency (reviewed in [7,8]). These biological pheno-
types are tightly linked to its biochemical properties as a viral E3
ubiquitin ligase and its ability to interact with host-cell E2 ubiqui-
tin conjugating enzymes [9–11]. ICP0 mediates the ubiquitination
and proteasome-dependent degradation of numerous cellular pro-
teins through a variety of targeting mechanisms (reviewed in [7]).
Fig. 1. Schematic illustration highlighting the salient features of the ubiquitin pathway. The post-translational modiﬁcation of proteins through the covalent attachment of
ubiquitin (Ub) occurs through a sequential cascade of enzymatic events: (i) activation through ubiquitin E1 activating enzymes. (ii) Conjugation through pathway speciﬁc E2
ubiquitin conjugating enzymes. (iii) Ligation to substrate (Sub.) through pathway and substrate speciﬁc E3 ubiquitin ligases. Modiﬁcation typically occurs through the
formation of an isopeptide bond between ubiquitin and a solvent exposed lysine residue within the substrate. Illustration depicts the formation of a poly-ubiquitin chain
through the sequential modiﬁcation of the anchored ubiquitin molecule within the substrate. Ubiquitin modiﬁcation is dynamic and reversible (blue arrows) through the
activity of pathway speciﬁc deubiquitinating enzymes (DUBs).
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including intrinsic and innate host immunity [10,12–21], SUMO
modiﬁcation [12,22,23], centromere stability and the cell cycle
[24–28], and aspects associated with DNA repair [29–33] amongst
others. The ubiquitin ligase and substrate targeting properties of
ICP0 have also been shown to be inﬂuenced by its phosphorylation
status [34,35], affecting the outcome of HSV-1 pathogenesis and
reactivation from latency in animal model systems in vivo [36].
The RING-ﬁnger domain of ICP0 interacts with both class I
(UBE2D1/UbcH5a) and class II (UBE2E1/UbcH6) E2 ubiquitin
conjugating enzymes [6,9,37], and to efﬁciently catalyze the for-
mation of poly-ubiquitin chains on a variety of different substrate
proteins; including itself (auto-ubiquitination; [6,38]), USP7 [39],
p53 [40], RNF8 [31,33], poly-SUMO2 chains [22], and PML
[15,41], both in vitro and in vivo. Traditionally, the biochemical
properties of ICP0 as a RING-ﬁnger ubiquitin ligase have been
monitored using standard electrochemiluminescence (ECL)-based
western blot assays. However, quantitation of ICP0 biochemical
activity using this approach is limited due to poor detection
efﬁciencies of ubiquitinated products and the restricted linear
range of chemiluminescent signal with traditional western blot
approaches. Consequently, we have established a sensitive and
quantitative protocol to examine the kinetics of ICP0 biochemistry
in vitro through the use of near-infrared (IR) imaging of immuno-
blots probed with ﬂuorescent secondary antibodies. This method
can be used to quantitatively assess the biochemical properties
of RING-ﬁnger ubiquitin ligases in solution, their respective pheno-
types following mutation, and inhibitor studies thereof. This
methodology will therefore be useful in the identiﬁcation and
characterization of speciﬁc regions within ICP0 that inﬂuence its
biochemical activity and its corresponding ability to stimulate
the onset of HSV-1 lytic infection and viral reactivation from
latency.2. Material and methods
2.1. Recombinant proteins
Polyhistidine-tagged UBE2D1 (UbcH5a) and Glutathione-
S-transferase (GST)-tagged ICP0.241 (amino acids 1–241 of ICP0
encompassing the C3HC4 RING-ﬁnger domain) were puriﬁed from
bacterial extracts using afﬁnity isolation chromatography, as
described previously [6]. Polyhistidine-tagged E1 ubiquitin-
activating enzyme was puriﬁed from baculovirus-infected cellextracts, as described previously [6]. Wild-type ubiquitin (Sigma–
Aldrich; U6253) and methylated-ubiquitin (BostonBiochem;
U-501) were purchased from commercial sources.
2.2. In vitro ubiquitination assays
Ubiquitination assays were carried out in a ﬁnal reaction vol-
ume of 10 ll in 50 mM Tris (pH 7.5), 50 mM NaCl, 1 mM MgCl2,
and 5 mM ATP (Sigma–Aldrich; A7699) supplemented with 10 ng
E1, 40 ng of E2 (UBE2D1), and 90 ng of E3 (GST-ICP0.241) per reac-
tion. Reaction mixtures were activated by the addition of 1 lg of
wild-type or methylated-ubiquitin per reaction and incubated at
37 C for the speciﬁed times. For inhibition assays, reaction mix-
tures were incubated in the presence or absence of disodium
dihydrogen ethylenediaminetetraacetic acid (EDTA) for 5 min prior
to the addition of ubiquitin. Assays were terminated by the addi-
tion of 3 SDS–PAGE loading buffer supplemented with 8 M urea
and 100 mM Dithiothreitol (DTT). Samples were heat denatured
at 95 C for 10 min prior to SDS–PAGE (12% Bis–Tris NuPAGE;
Life Technologies). Proteins were transferred to 0.2 lm nitro-
cellulose membranes (GE Healthcare Life Sciences) using an XCell
II transfer module (Life Technologies) for 60 min at 30 V.
2.3. Western blot assay
Membranes were blocked in 0.45 lm ﬁltered phosphate buf-
fered saline (PBS) supplemented with 10% fetal calf serum (FCS)
for 60 min at room temperature. Primary and secondary antibody
incubations were performed in ﬁltered PBST–FCS (PBS supple-
mented with 0.1% Tween-20 and 10% FCS) at the desired antibody
dilution (as stated below) for 1 h at room temperature. Membranes
were sequentially washed three times in PBST for 5 min following
each antibody incubation and three times in 0.2 lm ﬁltered H2O
prior to scanning. Primary antibodies: monoclonal anti-ICP0
(11060 [1/1000]; [42]), anti-ubiquitin (P4D1 [1/1000]; SantaCruz
Biotech), and polyclonal anti-ICP0 (3678 [1/1000]; a kind gift from
David Davido, University of Kansas). Secondary antibodies: goat
anti-mouse and anti-rabbit IgG Dylight 800 and 680 (Cat# SA5–
35521/35568 [1/20,000]; Thermo Scientiﬁc).
2.4. Quantitation and analyses of mono- and poly-ubiquitin products
Membranes were scanned using an Odyssey CLx infrared imag-
ing system (LI-COR Biosciences) at a resolution of 84 lm and
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were quantiﬁed using Image Studio software (LI-COR) on raw
unprocessed data ﬁles. Regression analysis, R-squared (R2), and
1/2 Vmax values were calculated using Sigmaplot (Systat Software,
Inc). Images were exported as 600 ppi RGB or grayscale TIF ﬁles,
minimally processed in Adobe Photoshop, and annotated in
Adobe Illustrator (Adobe Systems Incorporated).3. Results
One of the reported advantages of near-IR imaging over stan-
dard chemiluminescence based western blotting methodologies
is the increased stability and dynamic range of its signal. In order
to examine the application of such imaging technology to study
the biochemical properties of ICP0 in solution, we performed a ser-
ies of in vitro assays monitoring the ability of ICP0 to catalyze the
formation of unanchored poly-ubiquitin chains and mono-
ubiquitinated products in the presence of recombinant human
UBA1 (E1) and UBE2D1 (E2) enzymes under established assay con-
ditions [9]. Preliminary experiments demonstrated that secondary
antibody optimization was required in order to reduce uneven
ﬂuorescent background signal across the membrane, which indi-
rectly inﬂuenced the accurate quantitation of speciﬁc bands or
regions of interest (data not shown). It is recommended, therefore,
that both primary and secondary antibody concentrations are fully
optimized prior to quantitation for consistent and reproducible
results. Following a short series of optimization experiments, how-
ever, multiplex western blot assays analyzing the biochemical
properties of ICP0 in solution were readily achievable. Time course
experiments quickly established the advantages of near-IR imaging
over standard ﬁlm-based chemiluminescent methods by providing
simultaneous outputs for both ICP0 auto-ubiquitination (Fig. 2A;
red signal) and unanchored poly-ubiquitin chain formation
(Fig. 2A; green signal). Quantiﬁcation of three independent rounds
of unanchored poly-ubiquitin chain formation demonstrated a
strong correlation (R2 = 0.935) in the ability of ICP0 to stimulate
the formation of unanchored poly-ubiquitin chains over time
(1/2 Vmax = 28 min), which spanned two orders of magnitude in
relative intensity (Fig. 2B). Poly-ubiquitin chains were readily
quantiﬁable within 5 min of assay activation even though their
relative signal by eye was comparatively weak to that of ICP0
auto-ubiquitination (Fig. 2A and B).
In order to examine the use of near-IR imaging in the
quantiﬁcation of substrate ubiquitination, biochemical assays were(A)
Fig. 2. Quantitation of unanchored poly-ubiquitin chain formation by ICP0 using near
ICP0.241) were activated through the addition of wild-type ubiquitin (±Ub) and incubat
PAGE and analyzed by multiplex western blotting in conjunction with near-IR imaging f
mouse 800; green) and ICP0 auto-ubiquitination (pAb 3678 and Dylight anti-rabbit 680
panel) and corresponding single channel grayscale images (anti-ICP0 and anti-ubiquitin
ICP0 (Ub-ICP0), and unanchored poly-ubiquitin chains (Poly Ub) are highlighted. (B) Re
poly-ubiquitin chain formation were quantiﬁed and normalized with respect to the 90-m
depicts the mean intensity for each time point. Bars represent the standard errors of th
½ Vmax values were calculated using Sigmaplot (Systat Software, Inc).conducted in the presence of methylated-ubiquitin (MeUb): a
derivative of ubiquitin unable to form poly-ubiquitin chains due
to lysine methylation. As with wild-type ubiquitin (Fig. 2A), ICP0
was observed to readily undergo auto-ubiquitination in the pres-
ence of MeUb within 5 min of assay activation (Fig. 3A).
Quantitation of ICP0 auto-ubiquitination over time demonstrated
that 40% of the total input ICP0 was ubiquitinated within 90 min
(Fig. 3B and C). Moreover, using near-IR imaging it was also possi-
ble to quantify the accumulation of individual auto-ubiquitination
events over time (Fig. 3D and E). These data suggest that individual
lysine residues within ICP0 may undergo auto-ubiquitination in a
sequential manner, although future mutagenesis studies would
be required to validate this hypothesis. Taken together, we con-
clude that near-IR imaging provides a sensitive and robust system
to quantitatively analyze the ubiquitin ligase properties of ICP0 in
solution.
Using standard chemiluminescence methods we have pre-
viously shown that EDTA (a non-speciﬁc divalent cation chelator)
is able to competitively inhibit the RING-ﬁnger ubiquitin ligase
activity of ICP0 in a dose-dependent manner in vitro [43]. In order
to test the application of near-IR imaging for inhibitor screening,
we performed an inhibitor study using EDTA. Reaction mixtures
were incubated in the presence of increasing concentrations of
EDTA for 5 min prior to assay activation and incubation in the
presence of MeUb for 60 min (Fig. 4A). ICP0 auto-ubiquitination
activity was quantiﬁed over three independent experiments and
a dose–response curve calculated (Fig. 4B). Under these assay con-
ditions, the 50% inhibitory concentration (IC50) for EDTA was calcu-
lated to be 0.958 mM. In order to validate this inhibitory dose,
single concentration inhibitor assays were conducted and the
levels of ICP0 auto-ubiquitination quantiﬁed relative to the no drug
control (Fig. 4C). In the presence of 1 mM EDTA a 48% mean reduc-
tion in total levels of ICP0 auto-ubiquitination was observed
(Fig. 4D), independently verifying the sensitivity and reproducibil-
ity of this assay system. We conclude that near-IR imaging pro-
vides a robust platform of technology to assess the efﬁcacy of
small molecule compounds to inhibit ICP0 RING-ﬁnger ubiquitin
ligase activity in vitro.4. Concluding remarks
The ubiquitin–proteasome pathway plays a fundamental role in
the regulation of many viruses [4,5]. With the recent approval of
second-generation proteasome inhibitors in the treatment of(B)
-IR imaging. In vitro reaction mixtures containing E1, E2 (UBE2D1), and E3 (GST-
ed at 37 C for the speciﬁed time (mins). Reaction mixtures were resolved by SDS–
or the formation of unanchored poly-ubiquitin chains (mAb P4D1 and Dylight anti-
; red). (A) Representative image of a scanned immunoblot showing RGB (left-hand
; middle and right-hand panels, respectively). Unmodiﬁed ICP0, auto-ubiquitinated
gions of interest (ROI; dashed boxes right-hand panel in A) relating to unanchored
in time point in the presence of ubiquitin within individual experiments. Scatter plot
e means (SEMs) from three independent experiments. Regression analysis, R2, and
(A) (B) (C)
(E)(D)
Fig. 3. Quantitation of ICP0 auto-ubiquitination activity using near-IR imaging. Equivalent reaction mixtures (as described in Fig. 2) were activated by the addition of
methylated-ubiquitin (±MeUb: a ubiquitin derivative unable to support poly-ubiquitin chain formation) and incubated for the speciﬁc times (mins) at 37 C. Reaction
mixtures were analyzed by western blotting for ICP0 auto-ubiquitination (MeUb ICP0; mAb 11060 and Dylight anti-mouse 800). (A) Representative image of a scanned
immunoblot showing RGB and corresponding single channel grayscale image (top and bottom panels, respectively). (B) ROI relating to unmodiﬁed ICP0 (native; solid boxes)
and total auto-ubiquitinated ICP0 (modiﬁed; dashed boxes) were quantiﬁed for their respective signal intensities and normalized with respect to equivalent areas of the
membrane in the negative control (90-min time point in the absence of ubiquitin) within individual experiments. Bar graph depicts the relative intensity of native (light gray
bars) to modiﬁed (dark gray bars) ICP0 as a proportion of the total signal intensity (%). Means and standard deviations in modiﬁed ICP0 signal intensity from three
independent experiments are shown. (C) ROI relating to single lysine mono-ubiquitination events within ICP0 (dashed boxes; Ub1–Ub5) were individually quantiﬁed and
normalized with respect to equivalent areas of the membrane in the negative control (90 min in the absence MeUb; solid boxes). Bar graph depicts the relative fold increase in
individual lysine mono-ubiquitination within ICP0 over the time course of analysis (gray triangles). Black line depicts baseline following background normalization. Gray
dotted line represents one standard deviation from background. Means and standard deviations from three independent experiments are shown. Images shown are
representative and taken from a single experiment.
(A) (B) (C) (D)
Fig. 4. Quantiﬁcation of ICP0 ubiquitin ligase activity inhibition using near-IR imaging. Equivalent reaction mixtures (as described in Fig. 3) were incubated in the presence of
increasing concentrations of EDTA for ﬁve minutes prior to MeUb activation and incubation for 60 min at 37 C. Samples were analyzed by western blotting for ICP0 auto-
ubiquitination (MeUb ICP0; mAb 11060 and Dylight anti-mouse 800). (A) Representative image of a scanned immunoblot showing RGB and corresponding grayscale image
(top and bottom panels, respectively). (B) ROI representing ICP0 auto-ubiquitination (dashed boxes in A) were quantiﬁed for their respective signal intensities and normalized
within individual experiments with respect to the no drug control. Scatter plot depicts the mean intensity from three independent experiments at each concentration of EDTA
(mM). Regression analysis, R2, and IC50 values were calculated using Sigmaplot (Systat Software, Inc). Bars represent SEMs from three independent experiments. (C and D)
Validation of EDTA IC50 value. Equivalent reactions were performed in the presence or absence of 1 mM EDTA. Image highlights ROI used to quantify the levels of ICP0 auto-
ubiquitination. Bar graph depicts the relative fold decrease in total ICP0 mono-ubiquitination in the presence of EDTA. Means and standard deviations from three independent
experiments are shown.
6 C. Boutell, D.J. Davido /Methods 90 (2015) 3–7certain cancers [44], there is renewed interest for the identiﬁcation
of small molecule compounds that inhibit speciﬁc enzymes of the
ubiquitin–proteasome pathway to restrict the pathogenesis ofinfectious diseases within humans. Consequently, understanding
the biochemistry of viral regulators that utilize this pathway to
stimulate the progress of infection is likely to provide
C. Boutell, D.J. Davido /Methods 90 (2015) 3–7 7opportunities for the identiﬁcation and development of novel and
efﬁcacious antiviral compounds. Here we describe a protocol uti-
lizing near-IR imaging that provides a highly sensitive and linear
(over three-orders of magnitude; Fig. 3E) signal for the accurate
quantiﬁcation of ICP0 RING-ﬁnger ubiquitin ligase activity in solu-
tion. This methodology will prove valuable in the future identiﬁca-
tion of regions within ICP0 that inﬂuence its biochemical activity,
substrate targeting properties, and quantitation of mutants
thereof; for example ICP0-RING mutants with reduced E2 or sub-
strate binding afﬁnities [9]. Notably, this protocol can be readily
adapted to study other viral and cellular E3 ubiquitin ligases, and
applied in the biochemical characterization of small molecule com-
pounds identiﬁed to inhibit this important family of enzymes.
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